Table 2 Summary of studies used in the mouse proteomics meta-analysis.
Gil et al., 2024, PMID:Â 38,374,041 | |
---|---|
Mouse model | TDP-43 regulatable NLS8 (doxycycline (dox)-dependent inhibition of human cytoplasmic TDP-43 transgene) |
Tissue type | Cortex |
Sex | Female |
Age | From 10Â weeks of age |
Experimental groups | 1. Pre-onset—1 week off dox 2. Onset – 2 weeks off dox 3. Early disease – 4 weeks off dox 4. Late disease – 6 weeks off dox 5. Recovery – 6 weeks off dox and 2 weeks on dox |
Phenotype | - Motor deficits emerge at early disease (4Â weeks) with a decrease in muscle innervation, cortical neuron degeneration and astrogliosis - At late disease (6Â weeks) there is microglial dysfunction, spinal cord motor neuron degeneration and a dramatic motor deficit - Mice in recovery show clearance of cytoplasmic TDP-43, restoration of endogenous TDP-43 in neurons, muscle re-innervation from remaining neurons, and regain motor skills |
Gomes et al., 2024, PMID:Â 38,849,340 | |
---|---|
Mouse model | 1. TDP-43: B6;129S6Gt(ROSA)26Sortm1-(TARDBP*M337V/Ypet)Tlbt/J mice 2. SOD1: B6SJL-Tg(SOD1*G93A)1Gur/J mice 3. C9orf72: (Poly)GA-NES/C9orf72(R26(CAG-Isl-175GA) − 29 × Nes-Cre mice 4. FUS: Tg (Prnp-FUS)WT3Cshw/J mice |
Tissue type | Pre-frontal cortex |
Sex | Female & male |
Age | 1. 26Â weeks 2. 14Â weeks 3. 4.5Â weeks 4. 4Â weeks |
Experimental groups | Female & male: 1. TDP-43 2. SOD1 3. C9orf72 4. FUS |
Phenotype | - Pre-symptomatic stages (TDP-43 & SOD1 mice) - Early symptomatic (C9orf72) |
Matveeva et al., 2023, PMID:Â 37,779,364 | |
---|---|
Mouse model | 1. FUS: ΔFUS(1–359) mice 2. TDP-43: B6.Cg-Tg(Prnp-TARDBP*A315T)95Balo/J) |
Tissue type | Cortex |
Sex | 1. Female & male 2. Male |
Age | 1. PND 49–51 2. PND 57–62 |
Experimental groups | 1. FUS 2. TDP-43 |
Phenotype | Presymptomatic |
Whiteley et al., 2021, PMID:Â 33,277,362 | |
---|---|
Mouse model | 1. Ubqln2 KO mice (generated by insertion of loxP sites flanking the one exon of murine Ubqln2) 2. Ubqln2 KI containing mutant murine P520T Ubqln2 allele corresponding to the human disease-causing P506T mutation |
Tissue type | Brain, lumbar spinal cord or hippocampus |
Sex | Male |
Age | 1. Young (4–6 months) and old (12–16 months) 2. Young (4–6 months) |
Experimental groups | 1. Ubqln2 KO brain – young mice 2. Ubqln2 KO brain – old mice 3. Ubqln2 KO hippocampus – young mice 4. Ubqln2 KO spine – young mice 5. Ubqln2 KI hippocampus – young mice 6. Ubqln2 KI spine – young mice |
Phenotype | Animals have an intermediate, age-dependent neuromotor disease (10–14 months old) more severe than that seen in Ubqln2 knock-in mice |
Spiteri et al. 2025 (Current study) | |
---|---|
Mouse model | B6N.Cg-Tg(Prnp-TARDBP*Q331K)- 103Dwc/J mice |
Tissue type | Brain or spine |
Sex | Female |
Age | PND 180 |
Experimental groups | 1. Brain from TDP-43 mice 2. Spine from TDP-43 mice 3. Brain & spine (computationally merged) |
Phenotype | - Enhanced cytoplasmic mutant TDP-43 expression from 8Â weeks old - Progressive motor dysfunction beginning at 3Â months of age - A 43% reduction in hindlimb muscle mass by 6Â months12 |